XTX Topco Ltd Has $172,000 Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

XTX Topco Ltd lifted its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 7.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,134 shares of the biopharmaceutical company’s stock after acquiring an additional 773 shares during the period. XTX Topco Ltd’s holdings in Catalyst Pharmaceuticals were worth $172,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of CPRX. GAMMA Investing LLC increased its stake in Catalyst Pharmaceuticals by 72.9% in the first quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 819 shares in the last quarter. CWM LLC grew its holdings in shares of Catalyst Pharmaceuticals by 686.5% in the 2nd quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 3,549 shares during the period. Meeder Asset Management Inc. bought a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter valued at $70,000. Headlands Technologies LLC acquired a new stake in Catalyst Pharmaceuticals during the 1st quarter worth $154,000. Finally, Ameritas Investment Partners Inc. lifted its holdings in Catalyst Pharmaceuticals by 6.9% during the first quarter. Ameritas Investment Partners Inc. now owns 11,116 shares of the biopharmaceutical company’s stock worth $177,000 after acquiring an additional 720 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on CPRX. HC Wainwright increased their price target on Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Truist Financial raised their target price on shares of Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Oppenheimer reaffirmed an “outperform” rating and issued a $29.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, June 6th. Citigroup increased their price objective on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $29.50.

Catalyst Pharmaceuticals Trading Up 1.6 %

Shares of CPRX stock opened at $19.88 on Tuesday. The firm’s fifty day moving average price is $19.28 and its two-hundred day moving average price is $16.98. Catalyst Pharmaceuticals, Inc. has a 1 year low of $11.55 and a 1 year high of $21.67. The firm has a market capitalization of $2.35 billion, a P/E ratio of 36.81, a PEG ratio of 3.27 and a beta of 0.75.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.13. Catalyst Pharmaceuticals had a return on equity of 27.77% and a net margin of 15.69%. The business had revenue of $122.71 million for the quarter, compared to the consensus estimate of $111.76 million. As a group, equities research analysts forecast that Catalyst Pharmaceuticals, Inc. will post 1.82 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director David S. Tierney sold 15,000 shares of the stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total value of $301,500.00. Following the completion of the sale, the director now owns 348,874 shares of the company’s stock, valued at approximately $7,012,367.40. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, insider Carmen Jeffrey Del sold 36,058 shares of Catalyst Pharmaceuticals stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $18.42, for a total value of $664,188.36. Following the completion of the transaction, the insider now owns 12,369 shares of the company’s stock, valued at approximately $227,836.98. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director David S. Tierney sold 15,000 shares of the company’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total transaction of $301,500.00. Following the completion of the sale, the director now directly owns 348,874 shares in the company, valued at $7,012,367.40. The disclosure for this sale can be found here. Insiders have sold 201,058 shares of company stock valued at $4,018,188 in the last 90 days. 11.00% of the stock is currently owned by insiders.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.